We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+13.25%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$1.05B
AUM Growth
+$53.4M
Cap. Flow
-$44.1M
Cap. Flow %
-4.2%
Top 10 Hldgs %
70.43%
Holding
48
New
17
Increased
6
Reduced
6
Closed
15
Avg Time Held Equity + Options
2.5 quarters
Top 10 Avg Time Held Equity + Options
4.2 quarters
Top 20 Avg Time Held Equity + Options
2.9 quarters
Avg Time Held Equity only
2.8 quarters
Top 10 Avg Time Held Equity only
4.3 quarters
Top 20 Avg Time Held Equity only
2.9 quarters

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$50.1M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$35M
3
SGMO icon
SANGAMO THERAPEUTICS INC
SGMO
+$25.1M
4
UBX icon
Unity Biotechnology
UBX
+$24.6M
5
KZR icon
Kezar Life Sciences
KZR
+$22.2M

Top Sells

Rank Stock Value
1
ARRY icon
Array Biopharma Inc
ARRY
+$49.8M
2
WVE icon
Wave Life Sciences
WVE
+$45M
3
ASND icon
Ascendis Pharma A/S
ASND
+$23.6M
4
APLS icon
Apellis Pharmaceuticals
APLS
+$23.4M
5
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 87.08%
2 Miscellaneous 12.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
KYNB icon
1
Kyntra Bio
KYNB
$23.8M
$126M 12.02%
80,690
+593
+0.7% +$773K
2014 Q4
14 quarters
IRWD icon
2
Ironwood Pharmaceuticals
IRWD
$593M
$120M 11.38%
7,462,587
+435,201
+6% +$6.44M
2015 Q4
10 quarters
ASMB icon
3
Assembly Biosciences
ASMB
$414M
$115M 10.99%
245,264
– –
2014 Q4
14 quarters
ASND icon
4
Ascendis Pharma A/S
ASND
$14.7B
$97.4M 9.27%
1,464,067
-358,508
-20% -$23.6M
2016 Q3
7 quarters
KURA icon
5
Kura Oncology
KURA
$874M
$71.1M 6.77%
3,904,675
+137,823
+4% +$2.33M
2015 Q4
10 quarters
MDGL icon
6
Madrigal Pharmaceuticals
MDGL
$10.4B
$55.8M 5.31%
+199,500
New +$35M
2018 Q2
0 quarters
CELG
7
CALL
DELISTED
Celgene Corp
CELG
$46.5M 4.42%
585,000
+200,000
+52% +$16.6M
2017 Q4
2 quarters
SRRK icon
8
Scholar Rock
SRRK
$4.93B
$41.7M 3.97%
+2,671,161
New +$50.1M
2018 Q2
0 quarters
DRNA
9
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$36.3M 3.45%
2,961,147
-1,803,300
-38% -$22.7M
2017 Q1
5 quarters
MGNX icon
10
MacroGenics
MGNX
$218M
$30M 2.85%
1,450,606
– –
2017 Q4
2 quarters
ASND icon
11
CALL
Ascendis Pharma A/S
ASND
$14.7B
$29.7M 2.83%
+447,000
New +$29.4M
2018 Q2
0 quarters
RCUS icon
12
Arcus Biosciences
RCUS
$2.87B
$27.4M 2.61%
2,236,387
– –
2018 Q1
1 quarter
UBX icon
13
DELISTED
Unity Biotechnology
UBX
$25.3M 2.41%
+168,064
New +$24.6M
2018 Q2
0 quarters
KZR icon
14
DELISTED
Kezar Life Sciences
KZR
$22M 2.1%
+127,220
New +$22.2M
2018 Q2
0 quarters
KYNB icon
15
CALL
Kyntra Bio
KYNB
$23.8M
$21.9M 2.09%
14,000
+1,000
+8% +$1.3M
2017 Q4
2 quarters
SGMO icon
16
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$21.4M 2.04%
+1,509,671
New +$25.1M
2018 Q2
0 quarters
DNTH icon
17
Dianthus Therapeutics
DNTH
$4.34B
$20.8M 1.98%
+96,131
New +$21.7M
2018 Q2
0 quarters
GILD icon
18
CALL
Gilead Sciences
GILD
$183B
$20.7M 1.97%
+292,600
New +$20.7M
2018 Q2
0 quarters
IMDZ
19
DELISTED
Immune Design Corp.
IMDZ
$20.2M 1.92%
4,437,600
– –
2017 Q4
2 quarters
WVE icon
20
Wave Life Sciences
WVE
$619M
$15.8M 1.5%
412,871
-1,046,201
-72% -$45M
2017 Q3
3 quarters
SURF
21
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$14.5M 1.38%
+890,808
New +$12.9M
2018 Q2
0 quarters
EIGR
22
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$12.7M 1.21%
+34,650
New +$12.3M
2018 Q2
0 quarters
IRWD icon
23
CALL
Ironwood Pharmaceuticals
IRWD
$593M
$11M 1.05%
689,654
-107,699
-14% -$1.59M
2017 Q3
3 quarters
ACHN
24
DELISTED
Achillion Pharmaceuticals
ACHN
$11M 1.05%
3,887,407
+219,100
+6% +$746K
2017 Q4
2 quarters
KDMN
25
DELISTED
Kadmon Holdings, Inc.
KDMN
$9.97M 0.95%
+2,500,000
New +$9.76M
2018 Q2
0 quarters
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2018 Portfolio in Review

As of Q2 2018, EcoR1 Capital held 48 positions worth $1.05B, up 5.4% from $997M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

EcoR1 Capital withdrew a net $44.1M in Q2 2018, closing 15 positions and reducing 6 holdings. Its most notable exit was Array Biopharma Inc, an estimated $49.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 94% a quarter earlier, followed by Miscellaneous.

Against the trend, EcoR1 Capital opened a new position in Scholar Rock worth $41.7M.

  • EcoR1 Capital's largest Q2 2018 buy was Scholar Rock: 2,671,161 shares worth $41.7M.
  • EcoR1 Capital added most to Ironwood Pharmaceuticals in Q2 2018, an estimated $6.44M increase.
  • EcoR1 Capital's biggest Q2 2018 reduction was Wave Life Sciences, cutting an estimated $45M.
  • EcoR1 Capital fully exited Array Biopharma Inc in Q2 2018, selling an estimated $49.8M.
  • EcoR1 Capital's ten largest holdings make up 70% of its $1.05B portfolio in Q2 2018.
  • EcoR1 Capital opened 17 new positions and closed 15 in Q2 2018.
  • EcoR1 Capital's portfolio value rose 5.4% quarter-over-quarter to $1.05B.

Based on EcoR1 Capital's 13F filing for Q2 2018, filed 14 Aug 2018.